Genmab — Maj 2021
-
Det skal han passe lidt på med - det eneste han opnår er, at man ikke tror på hans guidance
-
Jeg har ikke lige adgang. - men Jan lader til at syntes godt om hexacd38 - https://finans.dk/erhverv/ECE12957058/genmabtopchef-ruger-paa-laegemiddelkandidat-der-er-op-til-100-gange-saa-potent-som-milliardhittet-darzalex/?ctxref=forside
-
God morgen.
-
orsdagens aviser med Mærsk, Vestas og Novo Nordisk https://www.proinvestor.com/investornyt/674792/torsdagens-aviser-med-maersk-vestas-og-novo-nordisk
-
SVB Leerink raises target price to $37 from $36
-
Nordea hæver til køb og målkurs på 2584
-
Guggenheim 2790
-
Fra 2656
-
-
DnB Markets
Rune Majlund Dahl
Genmab (Buy, TP: DKK2560.00) - Focus shifts to pipeline news flow
While Q1 revenue and EBIT were better than we expected, we believe the beat was primarily driven by lower opex. We expect the market’s focus to shift to the pipeline, with H2 likely to offer heavy news flow. We see a good chance of a guidance increase later in 2021. We reiterate our BUY and DKK2,560 target price. -
-
Any opinion on POLARIX trial? It was mentioned yesterday as a new treatment in early lines DLBCL if data would be good?
-
POLARIX from ASH 2020 https://www.roche.com/media/releases/med-cor-2020-12-07b.htm
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind